Japan is likely to see more than 20 new drugs from French pharma major Sanofi (Euronext: SAN) by 2020, said the newly-appointed Sanofi Japan chief executive Jacques Nathan at a press meeting held in Tokyo earlier this month.

Among these new drugs, which include existing drugs for new indications, “a significant amount will be biologics,” said Mr Nathan, reports Wang Fangqing, The Pharma Letter’s correspondent. (thepharmaletter.com)